For its first fiscal quarter (ending March 31), Zimmer Biomet Holdings Inc (NYSE: ZBH) has reported a -24% decline in E.P.S. from $1.11 a year ago to $0.84 in the current quarter. This performance was $-1.17 short of the consensus estimate of $2.01. E.P.S. were $4.64 for the latest four quarters through March 31 versus $2.14 for the same period a year ago — an increase of 117%.
Recent Price Action
Zimmer Biomet Holdings Inc (NYSE: ZBH) stock closed at $118.46 on 5/2/24 after a slight decline of -0.9%. Moreover, trading volume in this decline was exceptionally high at 231% of normal. The stock has performed in line with the market over the last nine months and has declined -2.2% during the last week.
Current PriceTarget Research Rating
With future capital returns forecasted to be above the cost of capital, ZBH is expected to continue to be an important Value Builder.
Zimmer Biomet Holdings has a current Value Trend Rating of C (Low Neutral). The Value Trend Rating reflects consistent signals from PTR’s two proprietary measures of a stock’s attractiveness. Zimmer Biomet Holdings has a slightly negative Appreciation Score of 35 and a neutral Power Rating of 60, resulting in the Low Neutral Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment